About this Research Topic
Fungal infections represent a major problem in human health care and difficult to treat. Despite advancements in antifungal medication, treatment in certain patients can still be difficult for reasons such as impaired organ function, limited administration routes, patient’s physical/physiological condition or poor safety profiles of the available antifungal medication. The growing number of invasive fungal species resistant to available antifungal medications is another major concern.
Triazoles act as important pharmacophores by interacting with the biological receptors with high affinity owing to their dipole character, hydrogen bonding capacity, rigidity and solubility. Triazole compounds are known to have potent antifungal properties. Itraconazole and fluconazole were some of the first triazoles synthesized, but had limitations associated with their use. Second-generation triazoles such as voriconazole, posaconazole, albaconazole, efinaconazole, ravuconazole and isavuconazole are all derivatives of either itraconazole or fluconazole, and designed to overcome the deficiencies of their parent drugs. The current status of fungal infections and the drawbacks of existing drugs demands for the development of more effective and safe antifungal agents with novel targets.
At this juncture, in the wake of many microbes becoming superbugs, concerted efforts of chemists and biologists are the most the most welcome thing. We welcome authors to contribute Original Research articles, Mini-Reviews, and Reviews that include synthesis of new triazole molecular hybrids possessing antifungal properties.
Triazoles act as important pharmacophores by interacting with the biological receptors with high affinity owing to their dipole character, hydrogen bonding capacity, rigidity and solubility. Triazole compounds are known to have potent antifungal properties. Itraconazole and fluconazole were some of the first triazoles synthesized, but had limitations associated with their use. Second-generation triazoles such as voriconazole, posaconazole, albaconazole, efinaconazole, ravuconazole and isavuconazole are all derivatives of either itraconazole or fluconazole, and designed to overcome the deficiencies of their parent drugs. The current status of fungal infections and the drawbacks of existing drugs demands for the development of more effective and safe antifungal agents with novel targets.
At this juncture, in the wake of many microbes becoming superbugs, concerted efforts of chemists and biologists are the most the most welcome thing. We welcome authors to contribute Original Research articles, Mini-Reviews, and Reviews that include synthesis of new triazole molecular hybrids possessing antifungal properties.
Keywords: Molecular hybridization, Antifungal activity, Antifungal resistance, Triazole, Antifungal activity Click chemistry
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
